Is Gpld1 legal in Australia?

A liver enzyme released into blood during exercise that transferred the cognitive benefits of running to sedentary aged mice. Higher in active older people; never administered to anyone.

In 2020 a Science paper reported that plasma from exercised aged mice, transfused into sedentary aged mice, transferred the effects of exercise on adult neurogenesis and cognition. Screening the plasma identified Gpld1, a liver-derived enzyme that cleaves glycosylphosphatidylinositol anchors, as rising after exercise and correlating with improved cognitive function in aged mice.

Mechanism: In mice, Gpld1 is a liver-derived enzyme released into plasma after exercise that cleaves glycosylphosphatidylinositol anchors, releasing GPI-anchored proteins from cell surfaces. The 2026 Cell work identifies GPI-anchored tissue-nonspecific alkaline phosphatase on brain endothelium as the substrate that carries the cognitive effect: cerebrovascular levels of that enzyme rise with age, mimicking that rise impaired blood-brain transport and cognition in young mice, and inhibiting it restored youthful hippocampal transcriptional signatures and rescued cognition in old mice.

Regulatory history: Not approved and never administered to a human. No interventional trial of Gpld1 is registered for any indication. The only registered human study using it is observational.

Registers or lists therapeutic goods on the ARTG and schedules substances in the Poisons Standard. Many peptides are Schedule 4 (prescription only), so possession without a prescription and personal importation are restricted even when no product is registered.

The classification above is the The Longevity Archive reading of Therapeutic Goods Administration listings for Gpld1 at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.